+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Delivery Devices Market by Device Type, End User, Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5031513
  • Report
  • March 2020
  • Region: Global
  • 201 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3M Company
  • AstraZeneca PLC,Becton
  • Consort Medical plc
  • Dickinson, Company
  • GlaxoSmithKline plc
  • InsuletCorporation
  • MORE
The global drug delivery devices market accounted for $19,061 million in 2018, and is expected to reach $26,742 million by 2026, registering a CAGR of 4.3% from 2019 to 2026.

Drug delivery is the process of administering a pharmaceutical compound to provide therapy to various diseases. The drug delivery technologies change the profile of drug release, including absorption, distribution, and elimination to improve product safety and efficacy. It also sees the patient convenience and compliance with the drug. The common routes of administration are the oral, enteral, parenteral, inhalation, topical, and transdermal patches routes. However, many medications such as protein and peptide, antibody, vaccine, and gene-based drugs may not be delivered through these routes of administrations, as they might be vulnerable to enzymatic degradation or cannot be absorbed into the systemic circulation efficiently. This is attributed to the molecular size and its therapeutic effects. Hence, many protein and peptide drugs are recommended to be delivered by injection. Recently, manufacturers are taking many efforts in the area of drug delivery, including the development of targeted drug delivery devices in which the drug is only active in the target area of the body.

The key factors that drive the growth of the drug delivery devices market include rise in The prevalence of chronic diseases and an increase in the biologics market. In addition, surge in geriatric population further supplements the growth of the market. However, risk of needle stick injuries and stringent government regulations hinder the growth of the market globally. On the contrary, high growth prospects in emerging markets can provide newer opportunities for the drug delivery devices market growth.

The drug delivery devices market size is studied on the basis of device type, route of administration, and region to provide a detailed assessment of the market. On the basis of device type, it is segmented into smart pills, inhalers, drug eluting stents, safety syringes, implantable drug delivery device, transdermal patches, and others. By route of administration, it is bifurcated into hospitals & diagnostic centers, ambulatory surgical centers & clinics, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • This report entails a detailed quantitative analysis along with the current global drug delivery devices market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments

By Device type
  • Smart pills
  • Inhalers
  • Drug eluting stents
  • Safety syringes
  • Implantable drug delivery device
  • Transdermal patches
  • Others
By End User
  • Hospitals & Diagnostic Centers
  • Ambulatory Surgical Centers & Clinics
  • Others
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
List of key players profiled in the report:
  • 3M Company
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Boehringer Ingelheim group
  • Consort Medical plc
  • GlaxoSmithKline plc,
  • Insulet Corporation, Medtronic Plc
  • Sulzer Ltd. (Medmix Systems AG)
  • West Pharmaceuticals Services, Inc
LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)
  • GlaxoSmithKline plc
  • Novo Nordisk A/S
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3M Company
  • AstraZeneca PLC,Becton
  • Consort Medical plc
  • Dickinson, Company
  • GlaxoSmithKline plc
  • InsuletCorporation
  • MORE
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Porter's five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rising The prevalence of chronic diseases
3.4.1.2. Growth in the biologics market
3.4.1.3. Rapid rise in the aging population
3.4.2. Restraints
3.4.2.1. Risk of needle stick injuries
3.4.2.2. Stringent government regulations
3.4.3. Opportunity
3.4.3.1. High growth prospects in the emerging markets
3.4.4. Impact Analyses

CHAPTER 4: DRUG DELIVERY DEVICES MARKET, BY DEVICE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Smart pills
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Inhalers and Nebulizers
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Drug Eluting Stents
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Safety Syringes
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Transdermal Patches
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

CHAPTER 5: GLOBAL DRUG DELIVERY DEVICES MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals and Diagnostic Centers
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Ambulatory Surgery Centers and Clinics
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: DRUG DELIVERY DEVICES CAMERA MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America Drug delivery devices market, by country
6.2.2.1. U. S.
6.2.2.1.1. U. S. Drug delivery devices market, by device type
6.2.2.1.2. U. S. Drug delivery devices market, by end user
6.2.2.2. Canada
6.2.2.2.1. Canada Drug delivery devices market, by device type
6.2.2.2.2. Canada Drug delivery devices market, by end user
6.2.2.3. Mexico
6.2.2.3.1. Mexico Drug delivery devices market, by device type
6.2.2.3.2. Mexico Drug delivery devices market, by end user
6.2.3. North America Drug delivery devices market, by device type
6.2.4. North America Drug delivery devices market, by end user
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe Drug delivery devices market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany Drug delivery devices market, by device type
6.3.2.1.2. Germany Drug delivery devices market, by end user
6.3.2.2. France
6.3.2.2.1. France Drug delivery devices market, by device type
6.3.2.2.2. France Drug delivery devices market, by end user
6.3.2.3. UK
6.3.2.3.1. UK Drug delivery devices market, by device type
6.3.2.3.2. UK Drug delivery devices market, by end user
6.3.2.4. Italy
6.3.2.4.1. Italy Drug delivery devices market, by device type
6.3.2.4.2. Italy Drug delivery devices market, by end user
6.3.2.5. Spain
6.3.2.5.1. Spain Drug delivery devices market, by device type
6.3.2.5.2. Spain Drug delivery devices market, by end user
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe Drug delivery devices market, by device type
6.3.2.6.2. Rest of Europe Drug delivery devices market, by end user
6.3.3. Europe Drug delivery devices market, by device type
6.3.4. Europe Drug delivery devices market, by end user
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific Drug delivery devices market, by country
6.4.2.1. Japan
6.4.2.1.1. Japan Drug delivery devices market, by device type
6.4.2.1.2. Japan Drug delivery devices market, by end user
6.4.2.2. China
6.4.2.2.1. China Drug delivery devices market, by device type
6.4.2.2.2. China Drug delivery devices market, by end user
6.4.2.3. Australia
6.4.2.3.1. Australia Drug delivery devices market, by device type
6.4.2.3.2. Australia Drug delivery devices market, by end user
6.4.2.4. South Korea
6.4.2.4.1. South Korea Drug delivery devices market, by device type
6.4.2.4.2. South Korea Drug delivery devices market, by end user
6.4.2.5. India
6.4.2.5.1. India Drug delivery devices market, by device type
6.4.2.5.2. India Drug delivery devices market, by end user
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific Drug delivery devices market, by device type
6.4.2.6.2. Rest of Asia-Pacific Drug delivery devices market, by end user
6.4.3. Asia-Pacific Drug delivery devices market, by device type
6.4.4. Asia-Pacific Drug delivery devices market, by end user
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA Drug delivery devices market, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Drug delivery devices market, by device type
6.5.2.1.2. Brazil Drug delivery devices market, by end user
6.5.2.2. South Africa
6.5.2.2.1. South Africa Drug delivery devices market, by device type
6.5.2.2.2. South Africa Drug delivery devices market, by end user
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia Drug delivery devices market, by device type
6.5.2.3.2. Saudi Arabia Drug delivery devices market, by end user
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA Drug delivery devices market, by device type
6.5.2.4.2. Rest of LAMEA Drug delivery devices market, by end user
6.5.3. LAMEA Drug delivery devices market, by device type
6.5.4. LAMEA Drug delivery devices market, by end user

CHAPTER 7: COMPANY PROFILES:
7.1.3M Company
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. AstraZeneca PLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. BECTON, DICKINSON AND COMPANY
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Boehringer Ingelheim group
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Consort Medical plc
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. GlaxoSmithKline plc
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Insulet Corporation
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Medtronic Plc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Sulzer Ltd. (Medmix Systems AG)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. West Pharmaceuticals Services, Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments


Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • 3M Company
  • AstraZeneca PLC,Becton
  • Consort Medical plc
  • Dickinson, Company
  • GlaxoSmithKline plc
  • InsuletCorporation
  • MORE
According to this report titled, 'Drug Delivery Devices Market by Device Type, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global drug delivery devices market size was valued at $19 billion in 2018, and is expected to reach $26.7billion by 2026, registering a CAGR of 4.3% from 2019 to 2026.

Drugs are used to improve health and to extend lives. However, the medications can be taken in various ways, including by swallowing, by absorption, by inhalation, through the skin, and by intravenous injection. For this, the drug delivery devices are developed, which are specialized tools for delivery of a therapeutic agent through the specific device type. Drug delivery systems control the rate at which a drug is released and the location in the body where it is released. Furthermore, these devices are used for the medical treatment for various chronic diseases. Moreover, the practice of drug delivery has changed dramatically in the past few decades and changes in the drug delivery technology are anticipated in the near future.

The major factor that contributes to the growth of the drug delivery devices market include rise in The prevalence of chronic diseases across the globe. Furthermore, other factors that boost drug delivery devices market growth include surge in geriatric population across the globe and a rise in the adoption of biologics worldwide. However, stringent government regulations associated with launch of new drug delivery devices hamper the growth of the drug delivery devices market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.

The drug delivery devices market size is studied on the basis of device type, route of administration, and region to provide a detailed assessment of the market. On the basis of device type, it is segmented into smart pills, inhalers, drug eluting stents, safety syringes, implantable drug delivery device, transdermal patches, and others. By route of administration, it is bifurcated into hospitals & diagnostic centers, ambulatory surgical centers & clinics, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

By product, inhalers &nebulizers acquired the major share of the drug delivery market in 2018 and is expected to continue this trend during the forecast period owing to factors such as surge in The prevalence of respiratory diseases such as asthma across the globe. Furthermore, other factors such as the rise in awareness related to the use of inhalers and nebulizers in treatment of respiratory diseases is another factor that boost the growth of the drug delivery devices market. In addition, smart pills segment is expected to exhibit the fastest CAGR owing to benefits associated with the use of these devices. For instance, smart pills have enabled monitoring of the results from different drug administrations which heavily assist in various stages of drug development such as drug c candidate profiling, drug c candidate selection, and accelerating the development of new drugs. Further, this emerging technology presents significant opportunity for the medical industry to exploit modern digital innovations and take a lead position in the future of healthcare.

By route of end user, hospitals and diagnostic centers acquired the major share of the market owing to surge in the prevalence of chronic disorders that require treatment which includes the use of drug delivery devices. In addition, ambulatory surgical centers is expected to exhibit the fastest CAGR during the forecast period owing to surge in number of ambulatory surgical centers across the globe.

By region, North America accounted for the major drug delivery devices market share in 2018 and is expected to continue this trend, owing to easy availability of drug delivery devices. Moreover, surge in the incidence of chronic diseases such as diabetes and cancer, is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of drug delivery devices. Moreover, the constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and South Korea.

According to Onkar Sumant, Manager, Healthcare, “The demand for drug delivery devices is on a rise, owing to surge in incidence of chronic diseases such as diabetes, cancer, and others worldwide. Furthermore, rise in healthcare expenditure leads to easy availability of drug delivery devices that fuels the market growth.”

KEY FINDINGS OF THE STUDY
  • Inhalers and nebulizers occupied more than one-thirds share of the global drug delivery devices market in 2018.
  • The hospitals and diagnostic centers segment in end user is anticipated to grow with the highest CAGR throughout the forecast period.
  • The transdermal patches segment in device type accounted for more than one-thirds share of the drug delivery devices market in 2018.
  • Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
Note: Product cover images may vary from those shown
4 of 5
  • 3M Company
  • AstraZeneca PLC,Becton
  • Dickinson, Company
  • Boehringer Ingelheim group
  • Consort Medical plc
  • GlaxoSmithKline plc
  • InsuletCorporation
  • Medtronic Plc
  • Sulzer Ltd. (Medmix Systems AG)
  • West Pharmaceuticals Services Inc
Note: Product cover images may vary from those shown
5 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll